Menopause Drug A Priority For Astellas

Fast Track For Fezolinetant

18 Aug 2022

The Japanese group has used a priority review voucher for fezolinetant to move further ahead of Bayer’s elinzanetant as it seeks regulatory approval to bring a non-hormonal therapy for menopausal symptoms such as hot flashes and night sweats to market.

Depression — Night sweats due to menopause seriously affect quality of life • Source: Shutterstock

In the race between Astellas Pharma, Inc. and Bayer AG to be the first pharmaceutical company to get approval for a non-hormonal menopause drug, the Japanese major has bagged a speedy review for fezolinetant, stealing a march on its German rival.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Can European Biotech Survive And Thrive In Era Of Instability?

30 Apr 2025

• By Andrew McConaghie

Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.